Aarkstore - Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2015 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Aarkstore - Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2015

Description:

Antibody-Drug Conjugate: Global Market and Pipeline Outlook, 2015, report provides the information across the ADCs drug value chain. The Report provides the marketed and pipeline scenario of the ADCs. Browse full report @ – PowerPoint PPT presentation

Number of Views:45

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Aarkstore - Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2015


1
Aarkstore - Antibody Drug Conjugate Insight
Pipeline Assessment, Technology Trend, and
Competitive Landscape, 2015
Category Pharmaceuticals and Healthcare
2
Summary
Antibody-Drug Conjugate Global Market and
Pipeline Outlook, 2015, report provides the
information across the ADCs drug value chain. The
Report provides the marketed and pipeline
scenario of the ADCs. The Report has covered the
264 Antibody-drug conjugates profile which gives
core information of the targets, mechanism of
action, development partner, Technology partner,
monoclonal antibody used, linker used and
cytotoxic drug with the descriptive information
of the technologies. The Report also provides the
assessment of the companys undergone
collaborations for technology and monoclonal
antibody and also gives insights over the
pre-clinical and clinical data. The Report has
also assessed the ADCs on geographical
distribution based on the country and region.
Browse Complete Report http//www.aarkstore.com
/pharmaceuticals-healthcare/106496/antibody-drug-c
onjugate-insight-pipeline-assessment-technology-tr
end-and-competitive-landscape
3
Report Facts
  • Antibody-Drug Conjugates (ADCs) are monoclonal
    antibodies (mAbs) attached to biologically active
    drugs by chemical linkers with labile bonds. The
    ongoing research on this therapy will replace the
    chemotherapeutics treatments in the near future
    thereby reducing its toxic side effects. Billions
    of dollars are spent on the chemotherapy
    treatments annually. Different Biotechnology
    companies and Pharma Companies are collaborating
    in all area of ADCs like linker technology,
    antibody production and conjugation process.
    Seattle Geneticss Brentuximab vedotin and
    Roches trastuzumab emtansine are the only ADCs
    approved which have together made USD 523
    millions sales in 2013. There are total 264 ADCs
    in pipeline with 253 ADCS are developing only for
    Oncology indications. Pipeline is very rich with
    four potential drugs in Phase III stage out of
    which Kadcyla and Adcetris are undergoing
    clinical studies for different conditions.

4
Scope
  •   A snapshot of the global Antibody-Drug
    Conjugate market scenario, market trends
    drivers, manacles of Antibody-Drug Conjugate. 
    A review of the marketed Antibody-Drug Conjugate
    products and marketing status  Coverage of
    global antibody-drug conjugate therapies under
    development across the globe covering
    territories  Competitive landscape of
    investigational products for key players and key
    therapy areas.  The Antibody-Drug Conjugate
    report covers the product description, stage of
    development, licensors collaborators,
    Development partner and Technology information

5
Reasons to buy
  • Complete Market and Pipeline intelligence and
    complete understanding over therapeutics
    development for Antibody-Drug Conjugate  Devise
    corrective measures for pipeline projects by
    understanding Therapy area specific therapies 
    Developing strategic initiatives to support your
    Antibody-Drug Conjugate development
    activities.  Optimize your portfolio and keep
    you in touch with the rapidly changing
    pharmaceutical markets, and make the best
    decisions for your business.

6
Table of Content
  • Introduction 13
  • Executive Summary 13
  • Scope of the Report 14
  • Antibody-Drug Conjugate Introduction 15
  • Historical Perspective of Antibody-Drug
    Conjugate 15
  • Design of Antibody-Drug Conjugate 17
  • Different components of Antibody-Drug Conjugate
    17
  • ImmunocongugateA distinct class of therapeutics
    in Oncology 20
  • Advantages of ADC over Traditional Therapies 21
  • Important Hurdles Faced in Development and
    Commercialization of ADC 22

7
List of Tables
  • Table 1 Marketed and Pipeline Antibody-Drug
    Conjugates, 2015
  • Table 2 Antibody-Drug Conjugate in Pipeline by
    Phase, 2015
  • Table 3 Therapeutic Areas under Research for
    Antibody-Drug Conjugate Products, 2015
  • Table 4 Number of Companies Targeting Different
    Therapeutics Areas in Antibody-Drug Conjugate
    Market Globally, 2015
  • Table 5 Number of Companies Targeting Different
    Therapeutics Areas in Antibody-Drug Conjugate
    Market Globally, 2015
  • Table 6 Number of Technologies with Companies
    for Antibody-Drug Conjugate Products Development,
    2015
  • Table 7 Number of Companies Technology for
    Antibody-Drug Conjugates Development, 2015
  • Table 8 Number of Companies with Monoclonal
    Antibodies for Antibody-Drug Conjugates
    Development, 2015

8
List of Figures
  • Figure 1 Marketed and Pipeline Antibody-Drug
    Conjugates, 2015
  • Figure 2 Phase III Antibody-Drug Conjugates and
    Trials, 2015
  • Figure 3 Comparison Graph for Discovery and
    Pre-clinical Antibody-Drug Conjugates, 2015
  • Figure 4 Antibody-Drug Conjugate in Pipeline by
    Phase, 2015
  • Figure 5 Therapeutic Areas under Research for
    Antibody-Drug Conjugate Products, 2015
  • Figure 6 Total Number of Companies Targeting
    Different Therapeutics Areas in Antibody-Drug
    Conjugate Market Globally, 2015
  • Figure 7 Number of Companies Targeting
    Different Therapeutics Areas in Antibody-Drug
    Conjugate Market Globally, 2015
  • Figure 8 Number of Technologies with Companies
    for Antibody-Drug Conjugate Products Development,
    2015
  • Figure 9 Number of Companies with Technology
    for Antibody-Drug Conjugates Development, 2015

9
Related reports
  • HER-2 Positive Breast Cancer Market in the US
    2015-2019
  • Global Small Cell Lung Cancer Therapeutics Market
    2015-2019
  • Global Osteoarthritis Market 2015-2019
  • Global Laboratory Information Management System
    (LIMS) Market 2015-2019
  • Global In-vitro Fertilization (IVF) Devices
    Market 2015-2019
  • Global Acute Coronary Syndrome (ACS) Market
    2015-2019
  • Global Automated External Defibrillator Market
    2015-2019
  • Global Gaucher Disease Market 2015-2019
  • Global In-vitro Fertilization (IVF) Devices
    Market 2015-2019
  • Global Laboratory Information Management System
    (LIMS) Market 2015-2019

10
  • Antibody Drug Conjugate Insight Pipeline
    Assessment, Technology Trend, and Competitive
    Landscape, 2015
  • Published Mar 2015 342 Pages
  • Antibody-Drug Conjugate Global Market and
    Pipeline Outlook, 2015, report provides the
    information across the ADCs drug value chain.
  • Price

Formatss Price
PDF 3500
Site License 7000
Enterprise Wide License 10500
11
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953
  • You Can Visit http//www.aarkstore.com
  • OR Mail us at contact_at_aarkstore.com
  • Blog
  • http//www.aarkstore.com/blog/
  • Conference
  • http//conference.aarkstore.com/
  • News
  • http//www.aarkstore.com/news
About PowerShow.com